Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2020–2024

HeatNMof · Heating triggered drug release from nanometric inorganic-metal organic framework composites

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2020-03-01 → 2024-08-31
EU contribution
€3,139,371
Participants
10
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

Heating triggered drug release from nanometric inorganic-metal organic framework composites

The HeatNMof project addresses a crucial challenge in cancer therapy: the need for precise drug delivery systems that enhance therapeutic efficacy while minimizing side effects. The project focuses on developing multifunctional nanomedicines based on Metal-Organic Frameworks (MOFs) combined with plasmonic or magnetic inorganic nanoparticles. These nanomedicines are engineered to specifically release drugs at targeted cancer sites using external stimuli like light or magnetic fields. Additional relevant properties (e.g. magnetic guiding, magnetic hyperthermia, photodynamic therapy, photothermal therapy, magnetic resonance imaging) allowed to further increase their antitumoral efficacy and selectivity. This precise control in drug administration together with advantageously combined effects (e.g. chemo-, photothermal, photodynamic-) not only improves treatment outcomes but also reduces collateral damage to healthy tissues, presenting significant advancements for both nanomedicine and oncology. The importance of this research for society lies in its potential to revolutionize cancer therapies by making treatments more effective and safer. By allowing for more precise localization of drugs, it opens the door to using more potent pharmaceuticals without harming healthy cells, which is a major limitation in current cancer treatments. Moreover, the ability to deliver multiple drugs in combination could offer solutions for complex diseases, paving the way for more comprehensive treatment strategies. The overall objectives of the HeatNMof project include: -Developing nanocarriers that can release drugs in response to external triggers (light and magnetic fields). -Enhancing the efficacy and reducing the side effects of cancer therapies through targeted delivery. -Combining diverse targeting, complementary therapies (i.e. chemotherapy, photodynamic therapy, hyperthermia) and imaging in a single highly efficient multifunctional nanomedicine. -Training early-stage researchers (ESRs) with advanced skills in nanomedicine, preparing them for future leadership roles in both academic and industrial sectors. -Establishing a foundation for future clinical applications of MOFs in nanomedicine, with follow-up research and potential collaborations already planned.

Data: CORDIS, © European Union

Project objective

Although recent advances in nanotechnology have provided an excellent platform to revolutionize the domain of health, the efficient and target delivery of many potent drugs in the body still remains an important challenge due to important drawbacks either from the drug (bioavailability, toxicity, etc.) and/or from the nanocarrier (biocompatibility, reproducibility, insufficient targeting). Consequently, there is currently a real demand for drug nanocarriers able to solve these matters for the different administration routes.HeatNMof project aims to develop smart multifunctional nanocarriers of challenging antitumoral drugs based on versatile highly porous biocompatible nanometric Metal Organic Frameworks, associated with exceptional drug payloads and controlled releases, and photo- and/or magnetic inorganic nanoparticles, providing both a specific control of reactions inside living entities (i.e. heating-triggered drug release) and additional properties such as imaging (magnetic resonance, thermal or optoacoustic imaging) and/ or hyperthermia therapy.The successful development of this project, involving academic and industrial partners, will contribute to the improvement of the highly societal relevant cancer therapy. This research objective is strongly related with the prime training/networking aim of HeatNMof: to train the next generation of materials scientists in a highly interdisciplinary and intersectorial research environment, such that they can soundly address upcoming challenges concerning nanomedicine, from the development, optimization and (physicochemical and biological) characterization of inorganic and hybrid materials, as well as their interaction with living entities, with a strong focus on drug delivery platforms based on nanomaterials. HeatNMof will train the next generation of material scientists with sound expertise in nanomedicine, highly needed to bring advanced materials as proposed from the bench to society.

Original text from CORDIS.

Participants

  • Fundacion IMDEA Energia · Mostoles MadridCoordinatorSpain
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
  • FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaItaly
  • IMMATERIAL LTD · CAMBRIDGEUnited Kingdom
  • INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE · ToulouseFrance
  • ISERN PATENTES Y MARCAS M SL · MADRIDSpain
  • NANOSCALE BIOMAGNETICS SOCIEDAD LIMITADA · ZARAGOZASpain
  • UNIVERSIDAD DE SANTIAGO DE COMPOSTELA · Santiago De CompostelaSpain
  • UNIVERSITEIT ANTWERPEN · AntwerpenBelgium
  • UNIVERSITY OF HAMBURG · HamburgGermany

Links

Data: CORDIS, © European Union